Luye Pharma’s Rivastigmine Patch Gains Approval in Japan

The latest announcement is out from Luye Pharma Group ( (HK:2186) ).

Luye Pharma Group Ltd. announced that its Rivastigmine Twice Weekly Transdermal Patch has been approved for marketing in Japan for treating mild to moderate Alzheimer’s disease. This innovative patch, marketed as Rivaluen® LA Patch, offers a lower application frequency compared to existing daily patches, potentially improving patient adherence and reducing gastrointestinal side effects. The company has partnered with Towa Pharmaceutical Co., Ltd. to commercialize the patch in Japan, and it is also approved in Europe and China, with plans for further registrations in Southeast Asia and Latin America.

More about Luye Pharma Group

Luye Pharma Group Ltd. is a pharmaceutical company that focuses on developing innovative drug formulations, particularly in the field of central nervous system therapeutics. The company is known for its proprietary platform for transdermal patches and has a market presence in multiple countries, including Japan, Europe, and China.

YTD Price Performance: -5.90%

Average Trading Volume: 100

Technical Sentiment Signal: Buy

Current Market Cap: $1.18B

For a thorough assessment of 2186 stock, go to TipRanks’ Stock Analysis page.